Abstract
Eltrombopag is a non-peptide thrombopoietin receptor agonist. Eltrombopag has originally been developed for conditions where therapy for thrombocytopenia is needed. Secondary to eltrombopag have been reported thrombotic events, chest pain, acute renal failure, neutropenia, ascites, retinal exudates, antiphospholipid syndrome. In this case, we present a 53 year-old patient who had diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) for 30 years with splenectomy. He’s still having low thrombocyte counts despite the classical ITP therapy. He was treated with eltrombopag for the last 2 months and had inferior myocardial infarction despite that having no additional risk factors for coronary heart disease.
Keywords: Eltrombopag, idiopathic thrombocytopenic purpura, myocardial infarction, thrombosis.
Current Drug Safety
Title:Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Volume: 11 Issue: 2
Author(s): Hakan Gunes and Tarik Kivrak
Affiliation:
Keywords: Eltrombopag, idiopathic thrombocytopenic purpura, myocardial infarction, thrombosis.
Abstract: Eltrombopag is a non-peptide thrombopoietin receptor agonist. Eltrombopag has originally been developed for conditions where therapy for thrombocytopenia is needed. Secondary to eltrombopag have been reported thrombotic events, chest pain, acute renal failure, neutropenia, ascites, retinal exudates, antiphospholipid syndrome. In this case, we present a 53 year-old patient who had diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) for 30 years with splenectomy. He’s still having low thrombocyte counts despite the classical ITP therapy. He was treated with eltrombopag for the last 2 months and had inferior myocardial infarction despite that having no additional risk factors for coronary heart disease.
Export Options
About this article
Cite this article as:
Gunes Hakan and Kivrak Tarik, Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction, Current Drug Safety 2016; 11 (2) . https://dx.doi.org/10.2174/1574886311207040255
DOI https://dx.doi.org/10.2174/1574886311207040255 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding
Current Cardiology Reviews Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Insulin Resistance in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety The Road to Device Miniaturization in Echocardiography
Recent Patents on Medical Imaging The Effects of Vitamin B in Depression
Current Medicinal Chemistry From fungus to pharmaceuticals – the chemistry of statins
Mini-Reviews in Medicinal Chemistry Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets
Current Protein & Peptide Science Circulating Levels of Uric Acid and Risk for Metabolic Syndrome
Current Diabetes Reviews Current and Future Insights in H. pylori Eradication Regimens: The Need of Tailoring Therapy
Current Pharmaceutical Design Postmenopausal Hormone Therapy
Current Women`s Health Reviews Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension
Current Vascular Pharmacology Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Cytokine Gene Variants as Predictors of Type 2 Diabetes Mellitus
Current Diabetes Reviews Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery